U.S. FDA approved Paxlovid, first oral antiviral for treatment of COVID-19 in adults
On May 25, 2023, the U.S. Food and Drug Administration (FDA) approved the oral antiviral Paxlovid (nirmatrelvir tablets…
-
-
U.S. Department of Health and Human Services ended the COVID-19 Public Health Emergency
On May 11, 2023, the U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra released the following…
-
NIH study identified features of Long COVID neurological symptoms
On May 5, 2023, the National Institutes of Health reported that a study had identified features of Long…
-
World Health Organization ended its declaration of COVID-19 as a global health emergency
On May 5, 2023, the World Health Organization (WHO) ended its declaration of COVID-19 as a global health…
-
Study raised concerns SARS-CoV-2 evolution outpaces vaccine-generated antibodies
On Apr. 27, 2023, a National Institute of Allergy and Infectious Diseases (NIAID) -led Phase 2 trial compared two…
-
U.S. state-by-state analysis of COVID-19 impact revealed driving forces behind variations in health published in The Lancet
On Apr. 23, 2023, the most comprehensive state-by-state analysis of the impacts of COVID-19 across the USA, published…
-
NanoViricides announced licensing agreement with Karveer Meditech to commercialize COVID drugs
On Apr. 4, 2023, NanoViricides announced that it had executed a license agreement with Karveer Meditech, Kolhapur, India,…
-
Antibiotics do not cut death risk in hospitalized patients with viral respiratory illnesses
On Mar. 24. 2023, antibiotics do not reduce the risk of dying in adults hospitalized with COVID-19, the…
-
Quest Diagnostics announced first-of-its-kind post-COVID-19 panels available
On Mar. 21, 2023, Quest Diagnostics announced that it had introduced two innovative Post-COVID-19 panels. These laboratory tests…
-
Biotechnology | COVID-19 | NIH | Pharmaceutical | Vaccine
SARS-CoV-2 infection weakens immune-cell response to vaccination
On Mar. 20, 2023, National Institutes of Health (NIH) scientists announced that the magnitude and quality of a…
-
FDA Advisory Committee voted in support of favorable benefit-risk profile for Pfizer’s PAXLOVID
On Mar. 16, 2023, Pfizer announced that the U.S. Food and Drug Administration’s Antimicrobial Drugs Advisory Committee (AMDAC)…
-
FDA authorized bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
On Mar. 14, 2023, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of…
-
Pfizer and BioNTech submitted for U.S. EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 booster in children under 5 years
On Mar. 1, 2023, BioNTech and Pfizer announced that they had submitted an application to the U.S. Food…
-
FDA authorized first OTC at-home test to detect both influenza and COVID-19 viruses
On Feb. 24, 2023, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for…
-
Moderna to provide free COVID-19 vaccines after U.S. public health emergency ends
On Feb. 15, 2023, Moderna announced it will continue to offer its COVID-19 vaccines for free, even after…
-
Biotechnology | COVID-19 | Diagnostics | FDA | Infectious Disease | Influenza | Vaccine
BD received FDA EUA for COVID-19, influenza A/B, RSV combination test
On Feb. 8, 2023, BD announced that it had received Emergency Use Authorization from the U.S. Food and…
-
Bivalent boosters provided better protection against severe COVID-19
On Feb. 7, 2023, an NIH funded study by University of North Carolina reported that Bivalent booster vaccines…
-
FDA announced Evusheld is not currently authorized for emergency use in the U.S.
On Jan. 26, 2023, the U.S. Food and Drug Administration revised the Emergency Use Authorization for Evusheld (tixagevimab…
-
Paxlovid reduced serious risks from Omicron variants
On Jan. 10, 2023, the U.S. National Institutes of Health (NIH) reported that antiviral treatments can help reduce…
-
Moderna received FDA EUA for Omicron-targeting bivalent COVID-19 booster vaccine in children 6 months through 5 years of age
On Dec. 8, 2022, Moderna announced it had received emergency use authorization from the U.S. Food and Drug…
-
Biotechnology | COVID-19 | Therapeutics | Vaccine | WHO
Novavax Nuvaxovid COVID-19 vaccine approved in Canada for use as a primary series in adolescents
On Dec. 7, 2022, Novavax announced that Health Canada had approved a supplement to a New Drug Submission…
-
Pfizer and BioNTech submit application to U.S. FDA for EUA of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years
On Dec. 5, 2022, Pfizer and BioNTech announced that the companies had submitted an application to the U.S….
-
Novavax updated EUA listing for Novavax Nuvaxovid COVID-19 vaccine as pimary series in adolescents and as booster in adults
On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing…
-
Novavax Nuvaxovid COVID-19 vaccine received expanded authorization in Canada as a booster in adults
On Nov. 18, 2022, Novavax announced that Health Canada had granted expanded authorization for Nuvaxovid (COVID-19 Vaccine (Recombinant…
-
Pfizer and BioNTech advancd next-generation COVID-19 vaccine
On Nov. 16, 2022, Pfizer and BioNTech announced that the companies had initiated a Phase 1 study to…
-
Novavax Nuvaxovid COVID-19 Vaccine authorized in the United Kingdom for use as a booster in adults
On Nov. 9, 2022, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
Novavax phase 3 COVID-19 Omicron trial supported continued and future use of prototype vaccine as a booster
On Nov. 8, 2022, Novavax announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS…
-
Moderna received Health Canada authorization for second Omicron-targeting bivalent booster
On Nov. 3, 2022, Health Canada authorized an adapted version of the Moderna Spikevax COVID-19 vaccine that targets…
-
Hologic announced contract with BARDA to support IVD approval of COVID assays
On Nov. 2, 2022, Hologic announced that it had been awarded a $19 million contract from the Biomedical…
-
USDA announced $30 million American Rescue Plan funding opportunity supporting research on SARS-CoV-2 in animals
On Nov. 1, 2022, the U.S. Department of Agriculture announced it was making $30 million in American Rescue…
